A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

October 28, 2020

Study Completion Date

October 28, 2020

Conditions
Pemphigus VulgarisPemphigus Foliaceus
Interventions
DRUG

ARGX-113

human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)

Trial Locations (12)

Unknown

University of Lübeck and UKSH, Department of Dermatology and Lübeck Institute of Experimental Dermatology, Lübeck

Clinic of Dermatology and Allergology - Philipps University Marburg, Marburg

University of Debrecen Medical Center Department of Dermatology, Debrecen

University of Pécs Clinical Center , Department of Dermatology, Venerology and Oncodermatology, Pécs

University of Szeged Faculty of Medicine Albert Szent-Györgyi Medical Center Department of Dermatology and Allergology, Szeged

HaEmek Medical center, Dermatology Department, Afula

Department of Dermatology, The Chaim Sheba Medical Center, Tel Aviv

Department of dermatology, The Tel Aviv Sourasky Medical Center, Tel Aviv

"Dermopathic Institute of the Immaculate - Foundation Luigi Maria Monti", Rome

Foundation Policlinico A. Gemelli - Dermatology Department, Rome

National Medical University named after O.O.Bohomolets, Department of Dermatology and Venereology based on Oleksandrivska Clinical Hospital of Kyiv City, Department of Dermatology, Kyiv

"Municipal Institution Zaporizhzhya Regional Dermatology and Venereology Clinical Dispensary of Zaporizhzhya Regional Council", Zaporizhzhya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY